Skip to main content

Table 1 Demographics and baseline characteristics

From: V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical results

 

Healthy volunteers n = 88

COPD patients n = 20

Male

88

12

Age, years

31.3 ± 8.8

60.4 ± 5.5

BMI, kg/m2

24.4 ± 2.9

24.5 ± 4.4

Time since diagnosis, years

NA

5.9 ± 4.4 (0.1–15.8)

Never smokers

75

-

Former smokers

13

20

Tobacco consumption, pack-years

NA

47.5 ± 25.1

FEV1, L

4.15 ± 0.53

1.23 ± 0.53

FEV1 (% predicted)

97.71 ± 10.28

43.40 ± 15.16

FVC, L

5.05 ± 0.66

2.76 ± 0.83

FVC (% predicted)

118.95 ± 13.76

98.03 ± 20.66

FEV1/FVC, %

82.43 ± 5.52

43.84 ± 10.41

FRC (% predicted)

-

180.28 ± 44.10

RV (% predicted)

-

220.71 ± 62.15

RV/TLC (% predicted)

-

164.86 ± 22.15

  1. Results are presented by mean ± SD (min-max) or number of patients (n)
  2. NA not applicable